The results from these studies support the concept that [89Zr]-malDFO-169 cDb can be used for CD8-targeted in vivo PET imaging in immune-competent mice bearing orthotopic glioma tumors treated with oHSV. This evidence concerns the gene CD8A and central nervous system cancer.